- Daklinza is an NS5A inhibitor indicated for use with sofosbuvir for the treatment of chronic HCV genotype 1 or 3 infection.
AND
AND
AND
AND
AND
OR
AND
Drug | Dosing Regimen | Dose Limit/ Maximum Dose |
---|---|---|
Harvoni* (sofosbuvir/ledipasvir) | One tablet PO QD for 12 weeks | 24 weeks |
Epclusa* | Without cirrhosis or with compensated cirrhosis, treatment naive or treatment experienced: One tablet PO QD | 12 weeks |
Epclusa plus ribavirin* | With decompensated cirrhosis (Child-Pugh class B or C) treatment naive or treatment experienced: One tablet PO QD plus weight based ribavirin | 12 weeks |
Drug | Dosing Regimen | Authorization Limit |
---|---|---|
Daklinza, Sovaldi | GT1 treatment naive or treatment experienced with Peg-IFN/RBV with or without protease inhibitor, and without cirrhosis: Daklinza 60 mg PO plus Sovaldi 400 mg PO QD | 12 weeks |
Daklinza, Sovaldi | GT1 treatment naive or treatment experienced with Peg-IFN/RBV with or without protease inhibitor, and with cirrhosis: Daklinza 60 mg PO plus Sovaldi 400 mg PO QD with or without weight based RBV | 24 weeks |
Daklinza, Sovaldi | GT1 with decompensated cirrhosis (including those with hepatocellular carcinoma): Daklinza 60 mg PO plus Sovaldi 400 mg PO QD with RBV | 12 weeks |
Daklinza, Sovaldi | GT1 with decompensated cirrhosis (including those with hepatocellular carcinoma) and intolerant to RBV: Daklinza 60 mg PO plus Sovaldi 400 mg PO QD | 24 weeks |
Daklinza, Sovaldi | GT2, treatment naive without cirrhosis, AND, unable to tolerate RBV: Daklinza 60 mg PO plus Sovaldi 400 mg PO QD | 12 weeks |
Daklinza, Sovaldi | GT2 who are not eligible to receive IFN, in whom previous treatment with Sovaldi/RBV has failed: Daklinza 60 mg PO plus Sovaldi 400 mg PO QD with or without RBV | 24 weeks |
Daklinza, Sovaldi | GT3, treatment naive or treatment experienced with Peg IFN/RBV without cirrhosis: Daklinza 60 mg PO plus Sovaldi 400 mg PO QD | 12 weeks |
Daklinza, Sovaldi | GT 3, treatment naive or treatment experienced with Peg IFN/RBV with cirrhosis: Daklinza 60 mg PO plus Sovaldi 400 mg PO QD | 24 weeks |
Daklinza, Sovaldi | GT 3 who are not eligible to receive IFN, in whom previous treatment with Sovaldi/RBV has failed: Daklinza 60 mg PO plus Sovaldi 400 mg PO QD with RBV | 24 weeks |
Daklinza, Sovaldi | GT 1, 2 or 3 infection in the allograft, including those with compensated cirrhosis: Daklinza 60 mg PO plus Sovaldi 400 mg PO QD with RBV | 12 weeks |
Daklinza, Sovaldi | GT 1, 2 or 3 infection in the allograft, including those with compensated cirrhosis and intolerant to RBV: Daklinza 60 mg PO plus Sovaldi 400 mg PO QD | 24 weeks |
Daklinza, Sovaldi | Reduce dosage to 30 mg PO QD with strong CYP3A4 inhibitors and increase to 90 mg PO QD with moderate CYP3A inducers. | This field intentionally left blank |
Tablets: 30 and 60 mg